The main thing that the Oncology Care Model (OCM) has brought is a shift in the mindset, said Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
The main thing that the Oncology Care Model (OCM) has brought is a shift in the mindset, said Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
Transcript
Does participating in value-based models like the Oncology Care Model help with the practice transformation needed for practices to have sustainable growth?
When you think about the OCM and what it’s brought to practices, I think the main thing it’s brought is a shift in the mindset. It has actually allowed practices to think about their practice differently and approach it differently. We look at technology differently now because before technology was seen as a nuisance, but with the value-based contracts and value-based arrangements, technology really allows you to get done what you need to get done. So, I think it has helped us in that way.
I think it has also helped the overall market because OCM came along and introduced a change throughout the market that wasn’t available prior. So, I think there we’ve seen a tremendous growth in opportunity, and we find that a lot of the other payers, commercial payers, are following the OCM to some degree.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More